Company
Headquarters: Tainan City, Taiwan
CEO: Mr. Fang-Yu Liu Ph.D.
TW$14.82 Billion
TWD as of July 1, 2024
US$455.0 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. It develops various general control release transmission system, including matrix system, reservoir system, matrix plus reservoir system, osmotic pump system, and colon delivery system. The company also develops modified release dosage forms, such as orally disintegrating tablets, modified release orally disintegrating tablets, modified release suspension systems, and ophthalmic modified release systems. Further, its Dexlansoprazole DR capsule, used for gastroesophageal reflux disease has obtained U.S. FDA approval; Varenicline tablet, used of smoking cessation aid, is under review with U.S. ANDA; and Fingolimod ODT, medication for multiple sclerosis is under review with U.S. 505(b) (2) NDA. In addition, it develops 505(b)2 and generic drugs. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Handa Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: TWSE: 6620 wb_incandescent